Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
28 Cards in this Set
- Front
- Back
MOA of lispro
|
Short-acting insulin
|
|
MOA of aspart
|
Short-acting insulin
|
|
T/F: Regular insulin is considered long-acting
|
False. It is short acting
|
|
MOA of neutral protamine Hagedorn (NPH)
|
Intermediate-acting insulin
|
|
MOA of glargine
|
Long-acting insulin
|
|
MOA of detemir
|
Long-acting insulin
|
|
Actions of insulin on liver, muscle and fat
|
Increased glycogen synthesis in liver; increase glycogen and protein synthesis in muscle; TG storage in fats; K uptake by muscle
|
|
What diabetic drug is a biguanide?
|
Metformin
|
|
These are the first generation sulfonylureas
|
Tolbutamide, chlorpropamide
|
|
These are the second generation sulfonylureas
|
Glyburide, glimepiride, glipizide
|
|
MOA of sulfonylureas
|
Close K channel in beta cells of pancreas, causing Ca influx and insulin release
|
|
These diabetic drugs are useless in type 1 diabetes
|
Sulfonylureas
|
|
Side effects of first generation sulfonylureas (tolbutamide, chlorpropamide)
|
Disulfiram-like effects
(avoid EtOH) |
|
Side effects of second generation sulfonylureas (glyburide, glimepride, glipizide)
|
Hypoglycemia
|
|
MOA of metformin
|
Unknown. Overall it acts as an insulin sensitizer. It is thought to decrease gluconeogenesis
|
|
Unlike sulfonylureas, this drug is not useless in type 1 diabetics because it does not require functioning islet cells
|
Metformin
|
|
Side effect of metformin
|
Lactic acidosis
|
|
These are the glitazones
|
Pioglitazone, rosiglitazone
|
|
MOA of glitazones
|
Sensitizes cells to insulin (like adiponectin, metformin)
|
|
Side effects of glitazones
|
Weight gain, edema, hepatotoxicity, cardiotoxicity
(cells are sensitized to insulin) |
|
MOA of acarbose
|
Brush border alpha-glucosidase inhibitor
|
|
MOA of miglitol (like acarbose)
|
Brush border alpha-glucosidase inhibitor
|
|
Side effects of acarbose and miglitol
|
GI upset
|
|
MOA of pramlintide
|
Decreases glucagon release
|
|
MOA of exenatide
|
Increase insulin release, decrease glucagon release
|
|
This drug is thought to cause pancreatitis
|
Exenatide (GLP-1 mimetic)
|
|
This drug is a GLP-1 mimetic (GLP-1 is a gut hormone that precipitate insulin release in response to blood glucose)
|
Exenatide
|
|
This drug is an oral hypoglycemic
|
Metformin (most others are injectibles)
|